Andere Sprachen Tenax Therapeutics, Inc.

Aktien

A3EVQN

US88032L6056

TENX

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:22:37 02.05.2024			% 5 Tage	% 1. Jan.
3,775 ^USD	-3,21 %		+4,44 %	-82,88 %

28.03.	Tenax Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
28.03.	Tenax Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	30.04.
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”	09.04.
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results	28.03.
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Tenax Therapeutics to Present at the 36th Annual Roth Conference	12.03.
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024	29.02.
Tenax Therapeutics Secures Global Rights for Levosimendan	20.02.
Tenax Therapeutics, Inc. and Orion Corporation Enters into an Amendment to Certain License Agreement	20.02.
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan	20.02.
Top Midday Decliners	08.02.
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected	08.02.
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Investors Await Economic Data	08.02.
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering	08.02.
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data	08.02.
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	08.02.
Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients	08.02.
Sector Update: Health Care Stocks Gain Late Afternoon	06.02.
Sector Update: Health Care	06.02.
Top Midday Gainers	06.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Tenax Therapeutics, Inc.

Aktien

A3EVQN

US88032L6056

TENX

Andere Sprachen

Filter